HIGHFDA DRUG

Teva Octreotide Acetate Injectable Suspension Recall Expanded in 2026 for Sterility Concerns

Teva Pharmaceuticals recalled 1,897 cartons of Octreotide Acetate for Injectable Suspension distributed nationwide in the USA after an FDA inspection flagged sterility concerns. The recall is due to lack of assurance of sterility from the contract manufacturer. Consumers and healthcare providers should stop using the product immediately and contact Teva for guidance.

Official notice

Source-backed recall notice

No product image was available from the source feed.

Official source
FDA DRUG
Recall date
March 17, 2026
Status
ACTIVE
Severity
8/10

Quick Facts at a Glance

Recall Date
March 17, 2026
Hazard Level
HIGH
Brands
OCTREOTIDE ACETATE, Teva Pharmaceuticals, Inc.
Category
Health & Personal Care
Sold At
Unknown
Geographic Scope
1 states
At-Risk Groups
GENERAL, PREGNANT, ELDERLY

What to Do Now

Use this page like a recall checklist: verify the product first, then act on the official remedy.

Immediate steps

  1. 1Stop using the product until you confirm whether it is included in the recall.
  2. 2Compare the product label, model number, UPC, color, size, and purchase location against the identifiers below.
  3. 3Follow the official remedy from FDA - Drug Safety; save photos, receipts, labels, and correspondence before contacting the company.
  4. 4If the product could harm a child, older adult, pet, or patient, move it out of reach immediately.

Check these identifiers

Brand
OCTREOTIDE ACETATE, Teva Pharmaceuticals, Inc.
Product type
Octreotide Acetate Injectable Suspension
Model numbers
Lot: 4401619, Exp.: 09/30/2026, 4501005, 03/31/2027.
UPC codes
0480-9257, 0480-9259, 0480-9262, 0480-9257-08, 0480-9256-01, 0480-9263-21, 0480-9259-08, 0480-9258-01 +2 more
Sold at
Unknown
Where affected
ALL

Recall Timeline

Key dates and source checks for this recall record.

  1. Recall announced

    March 17, 2026

  2. Reported by FDA DRUG

    April 1, 2026

  3. RecallRadar source check

    April 13, 2026

  4. Consumer action

    Use the official remedy and keep documentation.

Hazard Information

Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.

What You Should Do

Consumers and healthcare providers should stop using this product immediately. Contact Teva Pharmaceuticals USA, Inc or your healthcare provider for guidance. Notification method: Letter

About This Product

Octreotide acetate injectable suspension is a prescription medication used to treat certain hormone-secreting tumors and related conditions. It is administered by intramuscular injection, often in a clinical setting.

Why This Is Dangerous

The hazard is a sterility concern that could lead to contamination and infection if administered. The issue stems from quality control deficiencies identified during an FDA inspection of the contract manufacturer.

Industry Context

This recall is not presented as part of a broader industry pattern in the provided materials.

Real-World Impact

Patients currently receiving this medication may be affected. The recall covers nearly 1,900 cartons distributed nationwide, requiring clinicians to switch patients to alternative therapies as directed by Teva.

Practical Guidance

How to identify if yours is affected

  1. Verify the NDC 0480-9257-08 on the product label
  2. Check lot numbers 4401619 and 4501005
  3. Confirm expiry dates 09/30/2026 and 03/31/2027
  4. Confirm packaging states single-dose 8 mL vial, 10 mg

Where to find product info

FDA enforcement page for recall D-0404-2026 and Teva recall communications

What timeline to expect

Refund or replacement policies are not specified in the recall materials. Follow Teva guidance for next steps.

If the manufacturer is unresponsive

  • Contact Teva Pharmaceuticals USA, Inc for guidance
  • If no response within a reasonable timeframe, contact your healthcare provider or seek FDA MedWatch reporting

How to prevent similar issues

  • Verify supplier reliability with licensed pharmacies
  • Check lot numbers and expiry dates before administration
  • Avoid third-party suppliers for sterile injectables when possible
  • Ask clinicians to verify sterility certifications of suppliers

Documentation advice

Keep the recall notice and all packaging, labeling, and correspondence. Document lot numbers, expiry dates, and dates of contact with Teva or healthcare providers.

Get instant alerts for Health & Personal Care recalls

Be the first to know. Free instant alerts to your inbox.

No spamUnsubscribe anytime

Product Details

Model numbers/lot numbers: Lot 4401619; Exp. 09/30/2026; 4501005; Exp. 03/31/2027 Where sold: Nationwide in the USA When sold: Unknown Price: Unknown

Reported Incidents

No injuries or incidents have been reported.

Key Facts

  • Manufactured in Greece by Pharmathen International S.A. for Teva Pharmaceuticals
  • Sterility concerns identified during an FDA inspection

Safety Guide

Not sure what to do next? Our guide walks you through the process step by step.

Read: What to Do When You Find a Recalled Product

Get Alerts for Health & Personal Care Recalls

Get instant alerts for recalls that affect you. Free forever.

Safety Assessment

Risk LevelHIGH
Severity Score
8/ 10
Affected Groups
GENERALPREGNANTELDERLYINFANTSCHILDRENPETS
Injury Types
OTHER

Product Classification

Product Details

Model Numbers
Lot: 4401619
Exp.: 09/30/2026
4501005
03/31/2027.
UPC Codes
0480-9257
0480-9259
0480-9262
+7 more
Affected States
ALL
Report Date
April 1, 2026
Source Agency
FDA - Drug Safety
Recall Status
ACTIVE

Related Recalls